ADRB2 and lip and oral cavity carcinoma: On the other hand, the evidence that, in certain OSCCs, β2-AR expression by tumoral cells may decrease (Figure 1), as previously shown in patients with oral cancer and weak/negative β2-AR expression and low survival rates, compared with strong β2-AR expression [21], reinforces previous findings obtained by Yu et al. [10].